

# Contribution of Glucose Variability to HbA1C Levels in Patients With Type 1 Diabetes

Cardoso L<sup>1</sup>, Batista C<sup>1</sup>, Rodrigues D<sup>1,2</sup>, Barros L<sup>1</sup>, Moreno C<sup>1,2</sup>, Guelho D<sup>1</sup>, Vicente N<sup>1</sup>, Balsa M<sup>3</sup>, Martins D<sup>1</sup>, Oliveira D<sup>1</sup>, Carrilho F<sup>1</sup>

1. Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

2. Faculty of Medicine, University of Coimbra, Coimbra, Portugal

3. Department of Endocrinology, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal

## Background

Optimal management of type 1 diabetes requires full understanding of the relationships between the triad: HbA1C, fasting plasma glucose, and glucose variability (GV). Total glucose exposure, including postprandial hyperglycaemia and glucose variability, should be considered in the evaluation of the patient's risk for complications. As GV may contribute to hemoglobin glycation we assessed the influence of GV in HbA1C levels.


## Research Design and Methods

We retrospectively analysed 9,393 hours of continuous glucose monitorings (CGMs) from 61 patients with type 1 diabetes. Periods of 24 hours with missing values were excluded. We calculated various measures of GV and used a regression model to determine the impact of each GV measure to HbA1C level. GV was calculated using EasyGV<sup>®</sup> software and CGMs were recorded using iPro<sup>™</sup>2 (Medtronic, Northridge, CA).


### Sample Characteristics

Gender (female)	57%
Age (years)	30.0±9.2
Duration of T1D (years)	17.7±9.6
<b>Insulin therapy</b>	
MDI	63.5%
CSII	36.5%
Total daily dosage	44.8±20.5
BMI (Kg/m <sup>2</sup> )	22.8±7.6
HbA1C (%)	7.9±1.1


### A1C Percentiles



### Glycemic Variability



### Quality of Glycemic Control



### Glucose Variability

	A1C (%)				P
	< 7%	7-8%	8-9%	> 9%	
SD	2.8±1.1	3.4±0.8	3.8±0.8	4.24±1.1	<b>0.011</b>
CONGA	7.3±1.8	7.4±1.6	8.1±1.3	8.8±2.0	0.099
MAG	2.2±0.9	2.2±0.4	2.5±0.5	2.8±1.0	0.104
LI	5.3±5.3	5.4±2.3	7.3±3.4	9.3±6.1	<b>0.017</b>
MAGE-CGM	5.5±1.6	6.6±1.5	7.1±2.0	8.2±4.1	0.218
MODD	3.1±1.1	3.9±1.0	4.1±0.9	4.7±1.5	<b>0.041</b>
ADDR	21.1±11.5	26.3±8.9	32.6±9.9	37.0±12.5	<b>0.012</b>
M-value	12.9±7.3	15.0±6.6	16.5±7.3	23.0±13.8	0.333
J-index	42.0±16.0	46.0±18.0	55.3±15.7	66.8±26.6	<b>0.033</b>
HBGI	8.7±5.3	9.8±4.2	12.0±4.1	15.1±6.7	<b>0.041</b>
GRADE	7.2±4.7	7.0±3.7	8.3±3.4	9.9±5.6	0.396
%Hypoglycemia	10.9±13.0	14.7±14.7	9.3±9.9	9.3±10.8	
%Euglycemia	5.1±3.0	5.6±2.6	5.5±2.3	3.6±2.3	
%Hyperglycemia	84.0±12.8	79.7±15.5	85.1±9.9	87.1±10.9	

### A1C

### MODD

	Coefficient	P	Coefficient	P
SD	0.262	< 0.001	0.541	< 0.001
CONGA	0.373	< 0.001	0.450	< 0.001
MAG	0.264	< 0.001	0.464	< 0.001
LI	0.282	< 0.001	0.486	< 0.001
MAGE-CGM	0.192	< 0.001	0.441	< 0.001
MODD	0.329	< 0.001	-	-
ADDR	0.502	< 0.001	0.801	< 0.001
M-value	0.235	< 0.001	0.537	< 0.001
J-index	0.404	< 0.001	0.538	< 0.001
HBGI	0.353	< 0.001	0.566	< 0.001
GRADE	0.312	< 0.001	0.414	< 0.001

### Contribution of Intra and Interday Variability to A1C Levels

**Intraday Variability 4-16%**

SD: 10.2%, CONGA: 15.7%, MAGE: 3.9%, and MAG 8.1%, p<0.05

**Interday Variability 13%**

MODD: 13.1%

## Conclusion

GV contributes significantly to HbA1c levels. This effect is more pronounced at higher HbA1c levels. Interday variability was the most important contributor to HbA1C. GV impairs significantly the quality of glycemic control of type 1 diabetic patients.

